Edgewise Therapeutics, Inc. (EWTX) News
Follow Edgewise Therapeutics, Inc. (EWTX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Edgewise Therapeutics reports inducement grants under Nasdaq rules
Edgewise Therapeutics (EWTX) reports inducement grants as permitted by Nasdaq Listing Rules.
EQUITY | Sep 02, 2026, 12:00 PM UTC
L
Edgewise Therapeutics announces ESC Congress 2026 presentation
Edgewise Therapeutics says it will make an upcoming late-breaking science presentation at the European Society of Cardiology (ESC) Congress 2026.
GEOPOLITICS | Aug 24, 2026, 12:00 PM UTC
L
Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $36
Goldman Sachs analyst Paul Choi maintains Edgewise Therapeutics (NASDAQ: EWTX ) with a Neutral and raises the price target from $32 to $36.
EQUITY | Aug 11, 2026, 05:52 PM UTC
L
EWTX EWTX - Edgewise Therapeutics Reports Second Quarter 2026 Financial Results
EWTX EWTX - Edgewise Therapeutics Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 06, 2026, 12:01 PM UTC
L
Edgewise Therapeutics' EDG-7500 Seen Entering 'Catalyst-Dense' Regulatory Period, Oppenheimer Says
() -- Edgewise Therapeutics (EWTX) is entering a "catalyst-dense" period for EDG-7500, highlighted by an end-of-phase 2 FDA meeting in H2 and the planned start of a phase 3 study in Q4, Oppenheimer said in a Thursday not
REGULATION | Jul 09, 2026, 03:17 PM UTC
L
Buy Recommendation Issued On EWTX By Guggenheim
2026-07-06 09:15:08 ET Guggenheim analyst issues BUY recommendation for EWTX on July 6, 2026 12:17PM ET. <
EQUITY | Jul 06, 2026, 01:15 PM UTC